Evidence map›Paper›PMID 41026306›Full record

ReviewCurrent osteoporosis reports2025

Pathophysiology of Bone Fragility in Type 2 Diabetes Mellitus.

Eve Donnelly, Kendall F Moseley

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current osteoporosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eve DonnellyDepartment of Materials Science and Engineering, Cornell University, 326 Bard Hall, Ithaca, NY, 14853, USA. eld26@cornell.edu.ORCID http://orcid.org/0000-0001-8165-9568
Kendall F MoseleyDivision of Endocrinology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2500-2312

Funding

Defining and demystifying bone quality in type 2 diabetes mellitusK23DK093720 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI MOSELEY, KENDALL · 2012 to 2016
$924k
Nonenzymatic glycation, bone quality, and microdamage in type 2 diabetic boneK01AR064314 · NIAMS · CORNELL UNIVERSITY · PI DONNELLY, EVE · 2013 to 2017
$659k
NIDDK NIH HHS K23 DK093720NIH HHS K01 AR064314NIH HHS K23 DK093720
6 · The paper itself

Abstract

purpose of reviewIndividuals with type 2 diabetes mellitus (T2DM) are at greater risk of fragility fractures compared to those without diabetes despite comparable or higher bone mineral density (BMD). T2DM may increase skeletal fragility by altering aspects of bone quality including bone geometry, microstructure, tissue properties and remodeling independently of BMD, a parameter of bone quantity. The objective of this review is to synthesize recent work involving aspects of bone quantity and quality that may contribute to fragility in T2DM. RECENT

findingsCompared to those without diabetes, women with T2DM have less structurally robust hip geometries despite greater BMD after covariate adjustment. A growing body of evidence indicates that cancellous microarchitecture may be maintained in T2DM; however, cortical bone microarchitecture may be impacted by dysglycemia. Bone material properties - inclusive of tissue and/or compositional properties - and mechanical properties are influenced by T2DM. These include greater concentrations of advanced glycation end-products (AGEs) and increased tissue mineral content, changes associated with greater modulus and hardness, as well as reduced ductility and ability to mitigate damage accumulation. T2DM bone and serum markers indicate reduced bone remodeling compared to controls. Recent work bolsters prior observations reporting greater AGE and tissue mineral content in T2DM bone and reinforces findings of reduced remodeling. While some evidence indicates that these differences may adversely affect mechanical properties and result in stiffer, stronger - but more brittle - bone, this finding is not universal. Future studies require consideration of the multifactorial underpinnings of bone fragility in T2DM to guide screening, prevention strategies and fracture treatment in this at-risk population.

Indexed as

Bone and BonesDiabetes Mellitus, Type 2Osteoporotic FracturesBone DensityBone RemodelingGlycation End Products, AdvancedHumansGlycation End Products, AdvancedAdvanced glycation end-productsMaterial propertiesRemodelingType 2 diabetes

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.